TCTR20210927003招募中不适用
The Prevalence of HIV Elite Controllers, Viremic Controllers, False Elite Controllers, and False Viremic Controllers in Thai Blood Donors
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- N/A (No limit) 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. HIV Ag/Ab reactive (positive 3 times) or inconclusive (positive 2 times)
- •2. HIV NAT negative
排除标准
- •1. HIV Ag/Ab negative the first time or positive only 1 time from 3 times
- •2. HIV NAT positive
研究者
相似试验
招募中
4 期
A clinical trial to study the effects of fixed dose combination of Metoprolol and Telmisartan (Metosartan) in patients with essential hypertensioCTRI/2022/09/045464Sun Pharma Laboratories Limited SP
进行中（未招募）
1 期
A Phase IV, Single-Centre, Observer-Blind, Controlled, Randomized Study to Compare the Safety and Immunogenicity of Fluvirin® to Influvac® Administered to Healthy Children 3 to 12 Years of Age. - Fluvirin Paediatric TrialEUCTR2006-002649-35-GBovartis Vaccines and Diagnostics S.r.l.
尚未招募
3 期
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPYD599 Acquired haemolytic anaemia, unspecifiedAcquired haemolytic anaemia, unspecifiedD599PER-036-23REGENERON PHARMACEUTICALS, INC.
进行中（未招募）
不适用
Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin’s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic ChemotherapyPrevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas.MedDRA version: 13.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2008-007827-14-DEHelsinn Healthcare SA200
进行中（未招募）
不适用
Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin’s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic ChemotherapyPrevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas.MedDRA version: 12.0Level: LLTClassification code 10054133Term: Prophylaxis of nausea and vomitingEUCTR2008-007827-14-CZHelsinn Healthcare SA200